Allegro Ophthalmics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
31473 Rancho Viejo Rd Ste 204, San Juan ...Phone Number
(949) 940-8130Website
www.allegroeye.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Allegro Ophthalmics
Allegro Ophthalmics is focused on redefining the treatment of ocular diseases through integrin-regulating therapy. The company aims to develop groundbreaking treatments for eye care patients with limited options or inadequate responses to existing therapies, particularly targeting conditions like intermediate dry AMD and dry eye disease. Their innovative approach addresses mitochondrial dysfunction and oxidative stress response to create homeostatic harmony. Allegro is committed to meeting the unmet needs in ocular care and advancing clinical trials for their therapeutic pipeline.Explore more
Allegro Ophthalmics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Allegro Ophthalmics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Allegro Ophthalmics is spiking on competitors!
Earning: See what the market has to say on Allegro Ophthalmics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Allegro Ophthalmics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Allegro Ophthalmics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Allegro Ophthalmics launches new products
Allegro Ophthalmics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Allegro Ophthalmics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Allegro Ophthalmics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Allegro Ophthalmics
Compare insights from companies similar to Allegro Ophthalmics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Allegro Ophthalmics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Allegro Ophthalmics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Allegro Ophthalmics.
Allegro Ophthalmics financials insights
Gather financial insights about Allegro Ophthalmics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$20.3M
Grant
$2M
2017
Private Equity
$10.7M
Allegro Ophthalmics Tech Stack
A closer look at the technologies used by Allegro Ophthalmics
Most Recent Scoops
Executive Move
Board of Directors
Executive Move
Executive Moves, Lateral Move, Partnership, Personnel Moves, Board of Directors
Promotion
Executive Move
Executive Moves, Promotion, Personnel Moves
Funding
Funding
Allegro Ophthalmics News & Media
Allegro Ophthalmics Announces Presentation of Key Data Surrounding Dry AMD Pipeline Candidates, Treatment Considerations
- Intermediate Dry AMD Treatment Highlighted as Significant Unmet Need - Only Mitochondrial Stabilizing Candidates, Including Allegro's Risuteganib, Have Shown Best Corrected Visual Acuity (BCVA) Gains in this Patient Population SAN JUAN CAPISTRANO, Calif., Feb. 10, 2023 /PRNewswire/ --...U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)-- #AllegroEye--Allegro Ophthalmics, LLC announced that the results of the company's U.S. Phase 2a risuteganib dry AMD study published in the journal OSLI Retina.Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)-- #ASCRS2021--Allegro Ophthalmics announces positive results of ex-U.S. Phase 2 trial of ALG-1007 for the treatment of dry eye disease; FDA acceptance of IND.Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-US Phase 2 Trial of ALG ...
Allegro also announces FDA acceptance of IND for ALG-1007 for dry eye disease, clearing path to initiate Phase 2b/3 U.S. study ...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Allegro Ophthalmics
Sign Up For FreeTo access detailed company insights
Allegro Ophthalmics is focused on redefining the treatment of ocular diseases through integrin-regulating therapy. The company aims to develop groundbreaking treatments for eye care patients with limited options or inadequate responses to existing therapies, particularly targeting conditions like intermediate dry AMD and dry eye disease. Their inno... Read More
